Achillion Pharmaceuticals Inc

Achillion Pharmaceuticals — Technical Presentation (May 2019)

33 slides from Achillion Pharmaceuticals's technical presentation, May 17, 2019

  1. Slide 1: ACH-4471 in Combination with Eculizumab in Patients with PNH

    ©2019 Achillion Pharmaceuticals. All rights reserved. ACH-4471 in Combination with Eculizumab in Patients with PNH Interim Data from Phase 2 Clinical Trial ACH-4471: Factor D Complex May 17, 2019 Exhibit 99.1

  2. Slide 2: Forward-looking statements

    This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other important factors that could cause actual results to differ materially from those indicated by such forward-looking stat

  3. Slide 3: Table of Contents

    Section 1About ACH-4471 in PNH Section 2Interim Data from Phase 2 Dose Finding Study in Patients with PNH – Presented at New Era of Aplastic Anemia and PNH Meeting Napoli, Italy - May 17, 2019 Section 3 Potential Market Opportunity of ACH-4471 in Combination with C5 Inhibitors Table of Contents 5/17

  4. Slide 4: About ACH-4471 in PNH

    About ACH-4471 in PNH

  5. Slide 5: Paroxysmal Nocturnal Hemoglobinuria driven by deficient red blood cells

    Rare, acquired, blood disorder with remaining unmet medical need Two paths to PNH red blood cell (RBC) destruction driven by the alternative pathway (AP) Paroxysmal Nocturnal Hemoglobinuria (PNH) Driven by Deficient Red Blood Cells 1. Extravascular Hemolysis (EVH) C3b targets RBCs for destruction by

  6. Slide 6: Targeting Factor D, critical control point for alternative pathway

    Inflammatory Response Targeting Factor D (FD) Critical Control Point for Alternative Pathway Activity Promotes cell clearance (opsonization) leading to EVH Drives amplification loop Enables downstream C5 activity Classical Pathway Lectin Pathway Alternative Pathway FD C3a Amplification Loop C5 C5a C

  7. Slide 7: Up to 75% remain anemic with C5 inhibition only

    PNH Patients Treated with Eculizumab Up to 75% Remain Anemic with C5 Inhibition Only 1 Achillion Internal Physician Interviews of 14 US/EU KOLs 2018. 2 McKinley et al, ASH Dec 2017. Abst. 3471. 3 Hillmen et al. Br J Haematol. 2013. 4 Loschi et al. Am J Hematol. 2016. Hgb for Eculizumab-Treated Patie

  8. Slide 8: ACH-4471 experience in untreated PNH patients

    1.5x Upper Limit of Normal (ULN) Normal Hgb* Mean Hemoglobin Near Normal Range HEMOGLOBIN (MEAN +/- SD) Hemoglobin (g/dL) LDH (MEAN +/- SD) ACH-4471 Experience in Untreated PNH Patients Topline Results – December 2018 *Normal (female): 11.8-15.9 g/dL; Normal (male): 13.1-17.9 g/dL Individual subject

  9. Slide 9: ACH-4471 treatment experience moving towards Phase 3

    Completed 6- and 9-month chronic toxicology studies Completed renal & hepatic impairment study Completed thorough QT study Completed Development & Reproductive Toxicology studies Multiple DDI, ADME, and support studies Carcinogenicity studies - ongoing ACH-4471 Treatment Experience Moving Towards Ph

  10. Slide 10: Interim Data from Phase 2 Dose Finding Study in Patients with PNH

    Interim Data from Phase 2 Dose Finding Study in Patients with PNH Presented at New Era of Aplastic Anemia and PNH Meeting Napoli, Italy - May 17, 2019

  11. Slide 11: Presenter and clinical trial investigators

    Achillion Pharmaceuticals Presenter & Investigator Austin Kulasekararaj King's College Hospital-NHS Foundation Trust & King's College London, London, United Kingdom Investigators Robert Brodsky Johns Hopkins University School of Medicine, Baltimore, Maryland, United States Jaroslaw Maciejewski Cleve

  12. Slide 12: Study design: Phase 2 multi-center, open-label, multi-dose

    Per protocol, investigator determines clinical response and adjusts dose accordingly to a max of 200 mg TID EXTENSION STUDY Continue ACH-4471 plus eculizumab at same doses used at end of study Enrollment: up to 12 pts ACH-4471 in Combination with Eculizumab in PNH Patients Study Design- Phase 2 Mult

  13. Slide 13: Dose escalation per protocol

    Enrollment: up to 12 pts Dose Escalation Per Protocol *Dose escalations can be made after week 12 based on response Six-month Dose Finding Day 1 Week 4: Hgb has not increased by ≥1.5 g/dL from Day 1 OR Transfusion received during the previous 4 weeks Week 24 Week 8 Week 12 Week 4 On a patient-by-pat

  14. Slide 14: Baseline characteristics

    Baseline Characteristic N=11*, † Sex, n (%) N=11 Female 9 (82) Male 2 (18) Race, n (%) N=11 White 6 (55) Black or African American 3 (27) African Asian 1 (9) Asian 1 (9) Eculizumab Dosing (Q14D), n (%) N=11 900 mg 8 (73) 1200 mg 2 (18) 1500 mg 1 (9) Baseline Characteristics Baseline Characteristic N

  15. Slide 15: Baseline characteristics: laboratory parameters

    Baseline Characteristics Parameter Mean (SD) Median Range Hemoglobin* (g/dL)1 7.9 (1.5) 7.7 5.0-10.4 LDH (xULN)2 1.1 (0.32) 0.97 0.59-1.65 Reticulocytes (10^9/μl)3 219 (78) 200 120-405 Total Bilirubin (mg/dL)4 2.17 (1.12) 2.2 0.56-3.93 Direct Bilirubin (mg/dL)5 0.52 (0.22) 0.44 0.23-0.82 n=11; SD- s

  16. Slide 16: Transfusions prior to ACH-4471 administration

    Transfusions Prior to ACH-4471 Administration Baseline Transfusion N=10* RBC transfusions in 52 weeks prior to screening Number Units Total 54 97 Mean (SD) 5.4 (4.20) 9.7 (9.30) Range 1 -12 1 -27 RBC transfusions in 24 weeks prior to Screening Number Units Total 34 58 Mean (SD) 3.4 (2.59) 5.8 (4.94)

  17. Slide 17: ACH-4471 treatment durations

    ACH-4471 Treatment Durations Achillion Pharmaceuticals Patient Age/ Sex Dose (mg/TID) ACH-4471 Treatment Duration (months)* A 41/F 200 11 B 51/F 100 11 C 67/M 150 9 D 29/F 150 7 E 22/F 150 5 F 44/F 150 4 G 35/F 100 4 H 52/F 200 4 I 50/F 150 2 J 19/M 100 2 K F/57 100 1 Cumulative Summary ~59 months/4

  18. Slide 18: Combination therapy results in fewer transfusions

    Subject*, Sex, Age -52 to -25 Weeks -24 to -13 Weeks -12 Weeks to Screening Screening to Day 1 (≤60 Days) Day 1 to 12 Weeks 12-24 Weeks B, F 51 C, M 67 D, F 29 E, F 22 F, F 44 G, F 35 H, F 52 I, F 50 J, M 19 K, F 57 Combination Therapy Results in Fewer Transfusions *Patient A excluded from table due

  19. Slide 19: Meaningful improvement in hemoglobin compared to baseline

    Achillion Pharmaceuticals *Subjects with data available at each timepoint. All 11 subjects continue to receive treatment with ACH-4471. Data as of 10 May 2019. **Excludes Day 1 for patient K. Patient had Hgb 8.4 g/dL at screening. Patient received 1 unit PRBC Day -14 between screening and Day 1 resu

  20. Slide 20: Driving total bilirubin into normal range

    Driving Total Bilirubin into Normal Range Total bilirubin was driven into normal range at week 24 (n=4) versus baseline Achillion Pharmaceuticals *Subjects with data available at each timepoint. All 11 subjects continue to receive treatment with ACH-4471. Data as of 10 May 2019. * 5/17/2019 Normal R

  21. Slide 21: Driving direct bilirubin into normal range

    Driving Direct Bilirubin into Normal Range 7 of 11 patients had elevated direct bilirubin at screening 5 of 11 patients had direct bilirubin 1.5X ULN at screening No increase with ACH-4471 treatment with most patients actually showing decline in direct bilirubin Achillion Pharmaceuticals *Subjects w

  22. Slide 22: Marked reduction in reticulocyte count

    Marked Reduction in Reticulocyte Count Reticulocyte count was reduced to near normal at week 24 (n=4) Achillion Pharmaceuticals *Subjects with data available at each timepoint. All 11 subjects continue to receive treatment with ACH-4471. Data as of 10 May 2019. * 5/17/2019 Normal Range

  23. Slide 23: ACH-4471 PNH RBC Type III clone size

    ACH-4471 PNH RBC Type III Clone Size Achillion Pharmaceuticals Steady rise in PNH RBC Type III clone size *Subjects with data available at each timepoint. All 11 subjects continue to receive treatment with ACH-4471. Data as of 10 May 2019. Two samples were cancelled at week 24 due to sample stabilit

  24. Slide 24: Further reduction of LDH

    Further Reduction of LDH Achillion Pharmaceuticals Reduction of LDH into normal range versus baseline at week 24 (n=4) *Subjects with data available at each timepoint. All 11 subjects continue to receive treatment with ACH-4471. Data as of 10 May 2019. * 5/17/2019 Normal Range

  25. Slide 25: Improvement in FACIT-Fatigue scale

    Improvement in FACIT- Fatigue Scale Clinically Meaningful Improvement in Quality of Life: FACIT-Fatigue Scale Achillion Pharmaceuticals *Subjects with data available at each timepoint. All 11 subjects continue to receive treatment with ACH-4471. Data as of 10 May 2019 **Scores based on the FACIT Fat

  26. Slide 26: Treatment emergent adverse events

    Treatment Emergent Adverse Events* Number of TEAEs 53 Number of Patients Reporting a TEAE 11 (100%) MedDRA Preferred Term n (%) Headache 3 (27) Abdominal pain 2 (18) Contusion 2 (18) Cough 2 (18) Fatigue 2 (18) Nasopharyngitis 2 (18) Nausea 2 (18) Oropharyngeal pain 2 (18) Pain in extremity 2 (18) T

  27. Slide 27: Treatment emergent adverse events of interest

    Treatment Emergent Adverse Events of Interest Two patients each experienced a Grade 3/Severe TEAE: Grade 3 direct bilirubin elevation occurred in concert with a grade 1 ALT elevation at day 70 Both adverse events were resolved by Day 77 ACH-4471 dose was reduced temporarily from 150 mg TID to 100 mg

  28. Slide 28: Interim data showed a benefit from combination therapy with ACH-4471

    Interim Data in Transfusion Dependent Eculizumab Patients Showed a Benefit from Combination Therapy with ACH-4471 Benefits observed in multiple laboratory parameters Mean rise in hemoglobin relative to baseline Both total and direct bilirubin reduced into normal range Marked reductions in reticulocy

  29. Slide 29: Potential Market Opportunity of ACH-4471 in Combination with C5 Inhibitors

    Potential Market Opportunity of ACH-4471 in Combination with C5 Inhibitors

  30. Slide 30: Up to 75% of PNH patients on eculizumab remain anemic

    Up to 75% of PNH Patients on Eculizumab Remain Anemic Source & Periodical # Patients in Study % Anemic McKinley et al, ASH Dec. 2017 ABS 3471 141 72% Loschi et al: American Journal of Hematology 2016 123 72% Risitano et al: Blood 2009(1) 41 75.6%(2) 5/17/2019 Mean Hemoglobin was 10.5 g/dL across all

  31. Slide 31: Market opportunity for ACH-4471 combination therapy

    Market Opportunity for ACH-4471 Combination Therapy PNH C5 Inhibitor Clinical Segmentation1 ~4,000 C5 Inhibitor Treated PNH Patients (US/EU/Japan) ~ 15-20% Severely Anemic & Transfusion Dependent ~600 - 800 ~ 40-50% Anemic & Transfusion Independent ~ 1,600 - 2,000 ~ 10-15% Severely Anemic & Episodic

  32. Slide 32: Established market of C5 inhibitor patients in US, EU and Japan

    Established market of C5 inhibitor patients identified in the US, EU and Japan Current C5 inhibitor treatment is an established approach to treatment An Unmet Need: Blood transfusions and anemia are burden to patients Factor D inhibition plus C5 inhibition has the potential to significantly reduce t

  33. Slide 33: Our planned path forward in PNH therapy

    Our Planned Path Forward in PNH Therapy ACH-4471 PNH combination study w/eculizumab complete enrollment & targeting interim data for May 17, 2019 (n=11) ACH-4471 Study in Untreated PNH Patients Accepted for Oral Presentation at the 24th Congress of the European Hematology Association - June 15th 201

Achillion Pharmaceuticals — Technical Presentation (May 2019) on 6ix